Evidence map›Paper›PMID 34458285›Full record

ArticleFrontiers in medicine2021

Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 Pandemic.

Alberto Corrà, Francesca Cammelli, Lavinia Quintarelli, Giuseppe Barbato, Ornella Le Rose, Adele Salemme, Giovanni Di Zenzo, Francesco Coratti, Alice Verdelli, Cristina Aimo and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Alberto CorràSection of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Francesca CammelliDivision of Gastrointestinal Surgery, Careggi University Hospital, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Lavinia QuintarelliSection of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Giuseppe BarbatoDivision of Gastrointestinal Surgery, Careggi University Hospital, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Ornella Le RoseSection of Radiology, Unità Sanitaria Locale Toscana Centro, "Piero Palagi" Hospital, Florence, Italy.
Adele SalemmeMolecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
Giovanni Di ZenzoMolecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
Francesco CorattiDivision of Gastrointestinal Surgery, Careggi University Hospital, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Alice VerdelliSection of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Cristina AimoSection of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Elena Biancamaria MariottiSection of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Beatrice BianchiSection of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Fabio CianchiDivision of Gastrointestinal Surgery, Careggi University Hospital, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Marzia CaproniSection of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
University of Florence · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Usl Toscana Centro · ITIstituto Dermopatico dell'Immacolata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pemphigus vulgaris is an intraepidermal autoimmune mucocutaneous blistering disease whose etiopathogenesis includes various trigger factors, i.e., drugs and malignancies. We present a case of malignancy-exacerbated pemphigus vulgaris which required a careful diagnostic process in order to rule out paraneoplastic pemphigus, along with the challenges posed by the need of treating both cutaneous and oncologic diseases. Possible post-operative complications post-poned the start of first-line immunosuppressive treatment of pemphigus. Moreover, the infective risks had to be minimized during the peak of the COVID-19 pandemic in Italy. Intravenous immunoglobulins were chosen as "bridge" therapy before the tumor surgical excision, followed by rituximab in post-operative phase.

Indexed as

COVID-19esophageal cancerimmunoblotintravenous immunoglobulinIvor Lewis esophagectomyparaneoplastic pemphiguspemphigus vulgarisrituximab

Identifiers

PMID34458285
PMCPMC8385714
OpenAlexW3192241387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.